secwatch.observer — SEC 8-K summary
======================================

Issuer:     Moleculin Biotech, Inc. (MBRX)
CIK:        0001659617
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001437749-26-013083
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Moleculin's Annamycin extends survival >60% in metastatic pancreatic cancer preclinical models at AACR 2026
--------------------------------------------------------------------------------

- Median survival 29 days vs 18 days (p=0.0003) in metastatic PDAC models.
- Significant tumor volume reduction across multiple PDAC models (p<0.001).
- Higher tumor/pancreatic accumulation vs doxorubicin (p<0.0001).
- Induced CD8+ and CD4+ T-cell infiltration, suggesting immune activation.
- No cardiotoxicity observed; supports Annamycin's differentiated safety profile.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/0001437749-26-013083-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1659617/000143774926013083/mbrx20260422_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-013083

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer